A clinical trial at Seattle Children’s of a new drug called Trikafta has shown dramatic improvements in cystic fibrosis (CF) patients, and is projected to benefit up to 90% of all people with CF. Seattle Children’s Cystic Fibrosis Program participated in the phase 3 trial, and our On the Pulse blog describes the research science, the team of doctors and nurses involved at Children’s and the very personal impact on 17-year-old Ellie and her family.

“The first therapy approved for cystic fibrosis treated only about 7% of patients,” said Dr. Ron Gibson, director of Seattle Children’s Cystic Fibrosis Program. “Not only is this third-generation drug more robust, but it is treating the vast majority of patients with cystic fibrosis.”

Read the editorial published in the New England Journal of Medicine by National Institutes of Health director Dr. Francis Collins, who claims the results “should be a cause for major celebration.”

For more information on cystic fibrosis research trials at Seattle Children’s, please call 206- 987-3921 or visit our current research studies page.

Resources